why Xeris Biopharma Holdings Inc [XERS] is a Good Choice for Investors After New Price Target of $4.60

Xeris Biopharma Holdings Inc [NASDAQ: XERS] jumped around 0.29 points on Thursday, while shares priced at $2.53 at the close of the session, up 12.95%. The company report on January 4, 2024 at 7:00 AM that Xeris Biopharma Updates Its Outlook for 2023.

Company expects to be cashflow positive for the fourth quarter, report total revenue at the high end of its previous guidance of $160M-$165M, and end 2023 with over $72M in cash, cash equivalents, and short-term investments, exceeding its previous guidance of $65M-$70M.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Company to report Q4 and FY 2023 financial results on or about March 6, 2024.

Xeris Biopharma Holdings Inc stock is now 7.66% up from its year-to-date (YTD) trading value. XERS Stock saw the intraday high of $2.6701 and lowest of $2.32 per share. The company’s 52-week high price is 3.07, which means current price is +16.06% above from all time high which was touched on 01/04/24.

Compared to the average trading volume of 1.34M shares, XERS reached a trading volume of 5376489 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Xeris Biopharma Holdings Inc [XERS]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for XERS shares is $4.60 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on XERS stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Craig Hallum have made an estimate for Xeris Biopharma Holdings Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 28, 2023.

The Average True Range (ATR) for Xeris Biopharma Holdings Inc is set at 0.16, with the Price to Sales ratio for XERS stock in the period of the last 12 months amounting to 2.29. The Price to Book ratio for the last quarter was 90.39, with the Price to Cash per share for the same quarter was set at 0.48.

How has XERS stock performed recently?

Xeris Biopharma Holdings Inc [XERS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.21. With this latest performance, XERS shares gained by 33.86% in over the last four-week period, additionally plugging by 4.98% over the last 6 months – not to mention a rise of 125.89% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for XERS stock in for the last two-week period is set at 70.00, with the RSI for the last a single of trading hit 74.41, and the three-weeks RSI is set at 66.15 for Xeris Biopharma Holdings Inc [XERS]. The present Moving Average for the last 50 days of trading for this stock 1.92, while it was recorded at 2.35 for the last single week of trading, and 2.19 for the last 200 days.

Xeris Biopharma Holdings Inc [XERS]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Xeris Biopharma Holdings Inc [XERS] shares currently have an operating margin of -72.97 and a Gross Margin at +69.63. Xeris Biopharma Holdings Inc’s Net Margin is presently recorded at -85.86.

Return on Total Capital for XERS is now -37.72, given the latest momentum, and Return on Invested Capital for the company is -44.55. Return on Equity for this stock declined to -134.83, with Return on Assets sitting at -29.15. When it comes to the capital structure of this company, Xeris Biopharma Holdings Inc [XERS] has a Total Debt to Total Equity ratio set at 438.31. Additionally, XERS Total Debt to Total Capital is recorded at 81.42, with Total Debt to Total Assets ending up at 57.47. Long-Term Debt to Equity for the company is recorded at 434.81, with the Long-Term Debt to Total Capital now at 80.77.

Reflecting on the efficiency of the workforce at the company, Xeris Biopharma Holdings Inc [XERS] managed to generate an average of -$266,648 per employee. Receivables Turnover for the company is 4.57 with a Total Asset Turnover recorded at a value of 0.34.Xeris Biopharma Holdings Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.38 and a Current Ratio set at 1.82.

Insider trade positions for Xeris Biopharma Holdings Inc [XERS]

The top three institutional holders of XERS stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in XERS stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in XERS stock with ownership which is approximately 5.8325%.